0000000000300415

AUTHOR

Micha Löbermann

showing 3 related works from this author

Diagnosis and therapy of cutaneous and mucocutaneous Leishmaniasis in Germany

2011

The incidence of cutaneous and mucocutaneous Leishmaniasis (CL/MCL) is increasing globally, also in Germany, although the cases are imported and still low in number. The current evidence for the different therapies has many limitations due to lack of sufficient studies on the different Leishmania species with differing virulence. So far there is no international gold standard for the optimal management. The aim of the German joint working group on Leishmaniasis, formed by the societies of Tropical Medicine (DTG), Chemotherapy (PEG) and Dermatology (DDG), was to establish a guideline for the diagnosis and treatment of CL and MCL in Germany, based on evidence (Medline search yielded 400 artic…

Leishmaniasis Mucocutaneousmedicine.medical_specialtymedicine.medical_treatmentParomomycinCryotherapyDermatologyPharmacotherapyCutaneous leishmaniasisPregnancyGermanyparasitic diseasesmedicineHumansMiltefosineAntiparasitic Agentsbusiness.industryLeishmaniasismedicine.diseaseDermatologyLymphangitisPregnancy Complications ParasiticFemaleDermatologic AgentsbusinessFluconazolemedicine.drugJDDG: Journal der Deutschen Dermatologischen Gesellschaft
researchProduct

S1-Leitlinie Diagnostik und Therapie der kutanen und mukokutanen Leishmaniasis in Deutschland

2009

business.industryMedicineDermatologybusinessJournal der Deutschen Dermatologischen Gesellschaft
researchProduct

Vaccination in multiple sclerosis patients treated with highly effective disease-modifying drugs: an overview with consideration of cladribine tablets

2021

Infectious diseases are an important consideration in autoimmune conditions such as multiple sclerosis. Infective episodes may trigger relapses and significantly deteriorate the course of the disease. Some immunotherapies may cause increased rates of infection-related adverse events. Thus, infection and vaccine-related issues should be included in the individualized patient-specific treatment strategy and counseling before starting therapy and regularly on treatment. Clinical and epidemiological studies as well as pharmacovigilance data repeatedly demonstrated the safety of the great majority of vaccines in multiple sclerosis patients. Moreover, studies have shown that vaccinations with kil…

0301 basic medicinemedicine.medical_specialtyMedizincladribine tabletsDiseaseReviewimmunizationmultiple sclerosis1117 Public Health and Health Services03 medical and health sciences0302 clinical medicineNatalizumabInternal medicinevaccinePharmacovigilancemedicineddc:610CladribineAdverse effectRC346-42911 Medical and Health SciencesPharmacologybusiness.industryMultiple sclerosisCOVID-19Vaccine efficacymedicine.diseaseVaccinationCoronavirus030104 developmental biologyNeurology1107 ImmunologyNeurology (clinical)Neurology. Diseases of the nervous systembusiness030217 neurology & neurosurgerymedicine.drugTherapeutic Advances in Neurological Disorders
researchProduct